CJC-1295 + Ipamorelin 10mg — Vial Spec, Reconstitution Math & COA
A 10mg lyophilized vial containing a 1:1 ratio blend of CJC-1295 (No DAC) and Ipamorelin provides a high-yield dual-agonist reagent engineered for high-throughput preclinical research into pituitary growth hormone release. Designed exclusively for laboratory research use, this high-mass configuration supports long-term or multi-specimen protocols where volumetric precision and lot uniformity are critical. This technical overview detail reconstitution calculations, stability protocols, analytical certification, and handling procedures required for robust in vitro and animal models.
Quick answer
A 10mg lyophilized vial containing a 1:1 ratio blend of CJC-1295 (No DAC) and Ipamorelin provides a high-yield dual-agonist reagent engineered for high-throughput preclinical research into pituitary growth hormone release. Designed exclusively for laboratory research use, this high-mass configuration supports long-term or multi-specimen protocols where volumetric precision and lot uniformity are critical. This technical overview detail reconstitution calculations, stability protocols, analytical certification, and handling procedures required for robust in vitro and animal models.
Key takeaways
- A 10mg lyophilized vial of this combination blend contains 5mg of [CJC-1295](/research-peptides/cjc-1295-no-dac) (Mod GRF 1-29, without Drug Affinity Complex) and 5mg of [Ipamorelin](/research-peptides/ipamorelin) acetate, freeze-dried alongside a mannitol or trehalose bulking cake to ensure physical stability during transport and storage.
- [CJC-1295](/research-peptides/cjc-1295-no-dac) operates as a synthetic analog of growth hormone-releasing hormone (GHRH), selectively binding to and activating GHRH receptors on pituitary somatotropes.
- Accurate volumetric reconstitution of a 10mg total peptide mass requires precise mathematical planning prior to liquid addition.
- Lyophilized peptide cakes stored at -20°C remain stable for up to 24 months.
10mg Vial Configuration: Mass Breakdown and Research Utility
A 10mg lyophilized vial of this combination blend contains 5mg of CJC-1295 (Mod GRF 1-29, without Drug Affinity Complex) and 5mg of Ipamorelin acetate, freeze-dried alongside a mannitol or trehalose bulking cake to ensure physical stability during transport and storage. High-throughput bioassays, multi-cohort rodent studies, and automated pipette assays frequently utilize the 10mg vial size to maintain inter-assay consistency across large sample sizes without introducing lot-to-lot variable noise.
Researchers evaluating high-frequency sampling protocols benefit from the 10mg unit size because it minimizes vial changes during extended baseline testing. For investigators interested in acquiring this configuration, PX1 Research provides the direct CJC-1295 No DAC / Ipamorelin 10mg Blend manufactured under strict cGMP protocols, alongside our complete catalog of all research peptides for secondary evaluation.
Pharmacological Mechanism: GHRH and GHRP Synergism in Preclinical Models
CJC-1295 operates as a synthetic analog of growth hormone-releasing hormone (GHRH), selectively binding to and activating GHRH receptors on pituitary somatotropes. In animal models, CJC-1295 stimulates cyclic adenosine monophosphate (cAMP) accumulation through G-protein coupled receptor signaling, promoting gene transcription and basal secretion of endogenous growth hormone (GH). Studying CJC-1295 without DAC allows researchers to observe discrete, pulsatile release dynamics without the prolonged half-life associated with albumin-binding conjugates.
Ipamorelin functions as a selective growth hormone secretagogue receptor (GHSR-1a) agonist, mimicking the action of ghrelin. When administered simultaneously in preclinical assays, CJC-1295 and Ipamorelin exert a synergistic effect on somatotropes. In vitro pituitaries treated with both secretagogues exhibit amplification of total GH output significantly greater than the mathematical sum of either compound tested individually. Crucially, preclinical data show Ipamorelin does not stimulate adrenocorticotropic hormone (ACTH) or prolactin secretion, allowing clean, selective study of the somatotropic axis.
Reconstitution Calculations for 10mg Blend Vials
Accurate volumetric reconstitution of a 10mg total peptide mass requires precise mathematical planning prior to liquid addition. Because the vial contains a total active mass of 10,000 micrograms (5,000 µg CJC-1295 + 5,000 µg Ipamorelin), total diluent volume directly dictates final concentration per microliter (µL). Investigators can utilize our automated reconstitution calculator to verify custom concentrations, or rely on the baseline volumetric dilutions outlined below.
When reconstituting with 1.0 mL of sterile Bacteriostatic Water (0.9% benzyl alcohol), the resulting working concentration is 10 mg/mL (10 µg total peptide mass per 1 µL of solution). If reconstituted with 2.0 mL of diluent, the working concentration shifts to 5.0 mg/mL (5 µg total peptide per 1 µL). Reconstitution with 3.0 mL of diluent yields approximately 3.33 mg/mL (3.33 µg total peptide per 1 µL). For micro-volume dispensing in cell culture plates or precise micro-injections in rodent assays, a 2.0 mL dilution typically balances dissolution ease with volumetric accuracy.
Aliquot Management and Solubilization Stability Protocols
Lyophilized peptide cakes stored at -20°C remain stable for up to 24 months. However, once reconstituted into liquid state, peptide bonds become susceptible to hydrolytic degradation, oxidative cleavage, and temperature-driven denaturation. Repeated freeze-thaw cycles degrade structural integrity, precipitating peptide out of solution or cleaving fragile peptide bonds.
To maximize research yield and data reproducibility, reconstitute the 10mg vial using slow, gentle wall-drip technique with sterile diluent; never agitate or vortex the solution aggressively. Once fully solubilized, aliquot the master solution into sterile, single-use micro-centrifuge tubes based on projected daily usage parameters. Freeze working aliquots immediately at -20°C or -80°C. Thaw individual aliquots immediately prior to testing, discarding any un-utilized liquid after 24 hours at 4°C.
Analytical Rigor: HPLC/MS Verification and Lot-Matched COAs
Quantitative accuracy is vital for maintaining internal validity across preclinical trials. PX1 Research subjects every synthesis lot to rigorous analytical validation through independent ISO 17025 accredited testing laboratories. High-Performance Liquid Chromatography (HPLC) is conducted to verify chromatographic purity (guaranteed ≥99.0%), ensuring the absence of truncated sequences, deletion peptides, or synthesis reagents.
Mass Spectrometry (MS) is simultaneously performed to confirm exact molecular weight identities for both CJC-1295 (2,995.47 Da) and Ipamorelin (711.86 Da). Laboratory researchers can inspect the lot-matched Certificate of Analysis (COA) directly on our platform prior to deployment, guaranteeing that volumetric math calculated at the bench matches true chemical mass inside the vial.
Endotoxin Testing and Bio-Assay Compatibility
Bacterial endotoxins (lipopolysaccharides) introduced during peptide synthesis or processing can confound preclinical outcomes by activating inflammatory cascades, Toll-like receptor 4 (TLR4) pathways, and fever pathways in animal models. Standard chemical purity assays like HPLC do not detect endotoxins, making dedicated limulus amebocyte lysate (LAL) testing essential.
PX1 Research enforces strict endotoxin limits across all dual-blend products, guaranteeing endotoxin levels below 0.01 EU/mg. This level of purity ensures that observed biological responses—such as changes in cellular signaling, transcriptomics, or downstream IGF-1 expression—are attributable solely to peptide-receptor interaction rather than immunological contamination.
Comparative Analysis: CJC-1295 + Ipamorelin vs. Related Secretagogues
When designing protocols to investigate somatotropic axis stimulation, researchers frequently evaluate alternative GHRH analogs and growth hormone secretagogues. Comparing CJC-1295 + Ipamorelin against peptides like Sermorelin, GHRP-2, and Tesamorelin highlights distinct kinetic and receptor selectivity profiles.
Sermorelin represents a truncated 29-amino-acid GHRH fragment with a shorter biological half-life (~12 minutes in rodent models) compared to CJC-1295 (~30 minutes), requiring more frequent dosing protocols in dynamic secretion studies. GHRP-2 exhibits potent GH-releasing activity but causes concurrent elevation of cortisol and prolactin levels, introducing secondary hormonal variables. Tesamorelin possesses a trans-3-hexenoic acid modification engineered specifically for liver metabolism research, whereas CJC-1295 + Ipamorelin provides targeted somatotropic signaling with negligible affinity for glucocorticoid pathways.
Determining Optimal Vial Mass: 5mg vs. 10mg vs. Bulk Procurement
Selecting between a 5mg vial and a 10mg vial depends on total active assay volume, experimental timeline, and storage limitations. A 5mg total blend vial is ideal for small pilot studies or short-duration cell culture treatments where reconstituted peptide will be consumed within 5–7 days at 4°C, avoiding freeze-thaw degradation entirely.
Conversely, high-volume academic laboratories, contract research organizations (CROs), and multi-specimen animal studies benefit significantly from 10mg vials due to reduced per-milligram cost, lower shipping footprint, and reduced packaging waste. For large-scale research programs requiring bulk quantities or customized fill sizes, institutional buyers can review specialized supply pipelines through our wholesale laboratory channel or explore technical documentation in our peptide research library.
Frequently Asked Questions
What exact peptide mass is contained within a 10mg CJC-1295 + Ipamorelin vial?
The 10mg vial contains a 1:1 mass ratio consisting of 5mg CJC-1295 (Mod GRF 1-29, without DAC) and 5mg Ipamorelin acetate, total lyophilized mass equal to 10mg of active peptide reagent.
How do I calculate the concentration of a 10mg vial after adding 2mL of diluent?
Dividing 10mg (10,000 µg) by 2.0 mL yields a total peptide concentration of 5.0 mg/mL (5 µg per microliter of solution). This represents 2.5 µg of CJC-1295 and 2.5 µg of Ipamorelin per microliter.
Is CJC-1295 in this blend formulated with or without DAC?
This blend utilizes CJC-1295 No DAC (also known as Modified GRF 1-29). It does not contain the Drug Affinity Complex, allowing for rapid physiological clearance and pulsatile kinetic modeling.
Where can I view the lot-specific HPLC and MS reports for my vial?
Lot-matched Certificates of Analysis (COAs) featuring full HPLC chromatograms and Mass Spectrometry reports are publicly accessible via the PX1 Research COA portal using the lot number printed on the vial label.
What diluent is recommended for reconstituting this 10mg research peptide?
Sterile Bacteriostatic Water containing 0.9% benzyl alcohol is recommended for multi-use research applications over a 14-day window at 4°C. For immediate, single-use cell culture assays, sterile 0.9% Sodium Chloride or PBS may be used.
How long can reconstituted CJC-1295 + Ipamorelin remain stable at 4°C?
When reconstituted in Bacteriostatic Water under sterile conditions, the solution maintains biochemical integrity for up to 14–21 days at 2–8°C. For long-term storage, aliquoting and freezing at -20°C or -80°C is required.
What is the certified endotoxin threshold for PX1 Research peptide blends?
PX1 Research mandates strict quality controls ensuring all research peptides maintain endotoxin levels tested below 0.01 EU/mg, preventing immunological interference in sensitive cell culture or animal research models.
Are these compounds approved for human consumption or clinical administration?
No. All products supplied by PX1 Research are strictly engineered and distributed for in vitro, preclinical, and laboratory research use only. They are explicitly not intended for human, clinical, or veterinary applications.
Related pages
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.